AGER and diabetes mellitus: Inhibition or knockout of RAGE in the brain is accompanied by a reduction in neuronal damage and synaptic dysfunction, and an improvement in behavioral deficits in a mouse model of diabetes and neurodegenerative disease (Momeni et al., 2021b; Toth et al., 2007; Wang et al., 2018) indicated that RAGE may be a potential therapeutic target for DE.